Skip to main content

Phase II study of carboplatin in children with progressive low-grade gliomas.

Publication ,  Journal Article
Gururangan, S; Cavazos, CM; Ashley, D; Herndon, JE; Bruggers, CS; Moghrabi, A; Scarcella, DL; Watral, M; Tourt-Uhlig, S; Reardon, D; Friedman, HS
Published in: J Clin Oncol
July 1, 2002

PURPOSE: To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas. PATIENTS AND METHODS: Eligible patients received carboplatin 560 mg/m(2) intravenously every 4 weeks for 1 year after maximum tumor response or until disease progression or unacceptable toxicity. RESULTS: Between October 1993 and October 2000, 81 children (median age, 79 months; range, 6 to 204) were enrolled onto this study. Patients received a median of 11 cycles of carboplatin (range, one to 29). Median follow-up from the time of enrollment was 55 months (range, 10 to 93). The overall objective response (complete response [CR] + partial response [PR] + minor response [MR]) and disease stabilization (CR + PR + stable disease + MR) rates to carboplatin treatment were 28% (95% confidence interval [CI], 18% to 38%) and 85% (95% CI, 74% to 93%), respectively. Eleven and 14 patients suffered progressive disease on study and after stopping therapy, respectively. Toxicity was predominantly myelosuppression and included grade 3/4 neutropenia in 56 patients and grade 3/4 thrombocytopenia in 40 patients. The 3-year failure-free survival (FFS) and overall survival (OS) for all patients were 64% (95% CI, 54% to 76%) and 84% (95% CI, 76% to 93%), respectively. Patients with diencephalic tumors had inferior FFS and OS compared with those with tumor at other sites (38% v 74% for FFS, P =.011; 54% v 91% for OS, P =.004). Neurofibromatosis type 1 patients with progressive low-grade glioma had a significantly better OS (95% v 80%; P =.052). CONCLUSION: Carboplatin, in the schedule used in this study, produced disease stabilization or improvement in a majority of children with progressive low-grade glioma, with manageable toxicity. Improved treatment strategies are particularly required for patients with diencephalic tumors.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

July 1, 2002

Volume

20

Issue

13

Start / End Page

2951 / 2958

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Infusions, Intravenous
  • Infant
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gururangan, S., Cavazos, C. M., Ashley, D., Herndon, J. E., Bruggers, C. S., Moghrabi, A., … Friedman, H. S. (2002). Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol, 20(13), 2951–2958. https://doi.org/10.1200/JCO.2002.12.008
Gururangan, Sridharan, Christina M. Cavazos, David Ashley, James E. Herndon, Carol S. Bruggers, Albert Moghrabi, Deborah L. Scarcella, et al. “Phase II study of carboplatin in children with progressive low-grade gliomas.J Clin Oncol 20, no. 13 (July 1, 2002): 2951–58. https://doi.org/10.1200/JCO.2002.12.008.
Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951–8.
Gururangan, Sridharan, et al. “Phase II study of carboplatin in children with progressive low-grade gliomas.J Clin Oncol, vol. 20, no. 13, July 2002, pp. 2951–58. Pubmed, doi:10.1200/JCO.2002.12.008.
Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951–2958.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

July 1, 2002

Volume

20

Issue

13

Start / End Page

2951 / 2958

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Infusions, Intravenous
  • Infant
  • Humans